Gastric Cancer
Conditions
Keywords
tumor regression grade, radiomics, neoadjuvant chemotherapy, advanced gastric cancer, chemotherapy benefit
Brief summary
Neoadjuvant chemotherapy (NC) is an important treatment for advanced gastric cancer (AGC). However, tools that effectively predict the efficacy of NC before treatment are lacking. Computed tomography images before and after NC were used to construct a deep learning-based radiomics signature to predict the efficacy of NC, prognoses and postoperative adjuvant chemotherapy benefit.
Detailed description
Background: Neoadjuvant chemotherapy (NC) is an important treatment for advanced gastric cancer (AGC). However, tools that effectively predict the efficacy of NC before treatment are lacking. Methods: Computed tomography images before and after NC were used to construct a deep learning-based radiomics signature to predict the efficacy of NC, prognoses and postoperative adjuvant chemotherapy benefit. Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC). 193 patients with AGC from January 2010 to December 2018 in two different China university hospitals were included in this study. The before neoadjuvant chemotherapy imaging scoring system (BNCISS), imaging change scoring system before and after neoadjuvant chemotherapy (ICSS), which were constructed based on computed tomography images before after treatment.
Interventions
OTHERresponse to neoadjuvant chemotherapy
Tumor regression grade (TRG) =0 or 1 was defined as a good response to neoadjuvant chemotherapy (GRNC), and TRG=2 or 3 was defined as a poor response to neoadjuvant chemotherapy (PRNC).
Sponsors
Fujian Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Inclusion criteria
* Prospective collection and a retrospective analysis of patients seen from January 2010 to December 2018 at Fujian Medical University Union Hospital (FMUUH) and the First Hospital of Lanzhou University (FHLU) who were diagnosed with gastric adenocarcinoma and underwent radical resection
Exclusion criteria
* Patients with concurrent malignant disease, distant metastases, palliative resection, or gastric stump cancer were excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC for ICSS | 2022-01-01 to 2022-07-31 | The predictive performance of imaging change scoring system before and after neoadjuvant chemotherapy (ICSS) |
| AUC for BNCISS | 2022-01-01 to 2022-07-31 | The predictive performance of before neoadjuvant chemotherapy imaging scoring system (BNCISS) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | 2010-01-01 to 2022-07-31 | 3 year overall survival |
| disease free survival | 2010-01-01 to 2022-07-31 | 3 year disease free survival |
Countries
China
Outcome results
None listed